Recomienda este artículo a tus amigos:
TRAIL, Fas Ligand, TNF and TLR3 in Cancer - Resistance to Targeted Anti-Cancer Therapeutics Softcover reprint of the original 1st ed. 2017 edition
TRAIL, Fas Ligand, TNF and TLR3 in Cancer - Resistance to Targeted Anti-Cancer Therapeutics
Death receptors, including TRAIL-R1, TRAIL-R2, Fas and TNF-RI, owing to their ability to trigger apoptosis and to contribute to the elimination of cancer cells by the immune system have been considered, to variable extent, as important therapeutic targets for cancer therapy.
317 pages, 35 Illustrations, color; 5 Illustrations, black and white; XIII, 317 p. 40 illus., 35 ill
| Medios de comunicación | Libros Paperback Book (Libro con tapa blanda y lomo encolado) |
| Publicado | 12 de agosto de 2018 |
| ISBN13 | 9783319860060 |
| Editores | Springer International Publishing AG |
| Páginas | 317 |
| Dimensiones | 232 × 155 × 21 mm · 502 g |
| Lengua | Alemán |
| Editor | Micheau, Olivier |